Copy to clipboard 
ORTHOWORLD estimates Stryker’s 1Q17 orthopaedic revenue at US $1,612.3MM, +6.0% from 1Q16.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Joint Reconstruction | $868.5 | $822.2 | $47.0 | 5.6% |
| Knee | $486.2 | $450.0 | $36.2 | 8.0% |
| Hip | $353.5 | $344.7 | $8.8 | 2.6% |
| Extremities | $28.8 | $26.8 | $2.0 | 7.4% |
| Trauma | $327.7 | $303.0 | $24.7 | 8.2% |
| Arthroscopy/Soft Tissue | $118.0 | $109.5 | $8.5 | 7.7% |
| Spine | $173.4 | $169.1 | $4.3 | 2.6% |
| Orthobiologics | $53.0 | $49.7 | $3.3 | 6.7% |
| Other* | $71.7 | $68.4 | $3.3 | 4.8% |
| Total | $1,612.3 | $1,521.1 | $91.1 | 6.0% |
*Includes CMF, Performance Solutions
Performance highlights:
- Primary growth drivers remain consistent from past quarters, though now paired with solid performance in Australia, Canada and Europe: 3D printed products, foot/ankle portfolio (claiming very strong double-digit growth), Mako,
- Good momentum with endoscopy/sports medicine business, including 1588 camera
- U.S. spine still affected by supply issues, which should ease in 2Q
- In 2Q, launched System 8 power tools; other 2017 launches include additional 3D-printed products and re-launch of spine products that have been off the market for most of 2016
- In early innings with Tritanium, and noting “tremendous demand and interest from all of our implant businesses for 3D printed products”
Mako update:
- Installed 18 robots overall (11 in the U.S.) and continued to upgrade existing installs; expecting majority of robots in the field will be upgraded throughout 2017 and 2018
- Since launch of total knee application at AAOS, trained >200 surgeons at ~90 locations (U.S. and ex-U.S.)
- Australia and U.S. driving most of Mako’s momentum
Sources: Stryker Corporation; ORTHOWORLD estimates
Ranking Recap:
ORTHOWORLD’s 2016 estimates place Stryker at #3 in overall orthopaedic revenue, #2 in both joint recon and trauma and #4 in the spine and arthroscopy/soft tissue repair segments. Review these rankings in your copy of Orthopaedic Device Company Profiles: The Top 5.
ORTHOWORLD estimates Stryker’s 1Q17 orthopaedic revenue at US $1,612.3MM, +6.0% from 1Q16.
Q17
Q16
$ Change
% Change
Joint Reconstruction
$868.5
$822.2
$47.0
5.6%
...
ORTHOWORLD estimates Stryker’s 1Q17 orthopaedic revenue at US $1,612.3MM, +6.0% from 1Q16.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Joint Reconstruction | $868.5 | $822.2 | $47.0 | 5.6% |
| Knee | $486.2 | $450.0 | $36.2 | 8.0% |
| Hip | $353.5 | $344.7 | $8.8 | 2.6% |
| Extremities | $28.8 | $26.8 | $2.0 | 7.4% |
| Trauma | $327.7 | $303.0 | $24.7 | 8.2% |
| Arthroscopy/Soft Tissue | $118.0 | $109.5 | $8.5 | 7.7% |
| Spine | $173.4 | $169.1 | $4.3 | 2.6% |
| Orthobiologics | $53.0 | $49.7 | $3.3 | 6.7% |
| Other* | $71.7 | $68.4 | $3.3 | 4.8% |
| Total | $1,612.3 | $1,521.1 | $91.1 | 6.0% |
*Includes CMF, Performance Solutions
Performance highlights:
- Primary growth drivers remain consistent from past quarters, though now paired with solid performance in Australia, Canada and Europe: 3D printed products, foot/ankle portfolio (claiming very strong double-digit growth), Mako,
- Good momentum with endoscopy/sports medicine business, including 1588 camera
- U.S. spine still affected by supply issues, which should ease in 2Q
- In 2Q, launched System 8 power tools; other 2017 launches include additional 3D-printed products and re-launch of spine products that have been off the market for most of 2016
- In early innings with Tritanium, and noting “tremendous demand and interest from all of our implant businesses for 3D printed products”
Mako update:
- Installed 18 robots overall (11 in the U.S.) and continued to upgrade existing installs; expecting majority of robots in the field will be upgraded throughout 2017 and 2018
- Since launch of total knee application at AAOS, trained >200 surgeons at ~90 locations (U.S. and ex-U.S.)
- Australia and U.S. driving most of Mako’s momentum
Sources: Stryker Corporation; ORTHOWORLD estimates
Ranking Recap:
ORTHOWORLD’s 2016 estimates place Stryker at #3 in overall orthopaedic revenue, #2 in both joint recon and trauma and #4 in the spine and arthroscopy/soft tissue repair segments. Review these rankings in your copy of Orthopaedic Device Company Profiles: The Top 5.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
